drugset / Trial / NCT07686692
IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency
Phase 4
Not yet recruiting
300 enrolled
Duke University
Kaiser Permanente · collabNational Institute on Aging (NIA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This randomized, double-blind, placebo-controlled clinical trial evaluates intravenous ferric derisomaltose in older adults with HFpEF and iron deficiency.
Timeline
- Start
- 2026-08
- Primary completion
- 2030-08
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric Derisomaltose | Unknown | 500 mg | Intravenous |
| Subject | Ferric Derisomaltose | Unknown | 2000 mg | Intravenous |